Today's noteworthy initiations include: Alexion (ALXN) initiated with a Neutral at Credit Suisse... Alnylam (ALNY) initiated with an Outperform at Credit Suisse... Amgen (AMGN) initiated with an Outperform at Credit Suisse... Apigee (APIC) initiated with a Buy at Roth Capital... BioMarin (BMRN) initiated with an Outperform at Credit Suisse... Biogen (BIIB) initiated with a Neutral at Credit Suisse... Booz Allen (BAH) initiated with a Buy at Jefferies... CSI Compressco (CCLP) initiated with a Neutral at Janney Capital... CSRA (CSRA) initiated with a Buy at Jefferies... Celgene (CELG) initiated with an Outperform at Credit Suisse... Coherus Biosciences (CHRS) initiated with an Outperform at Credit Suisse... Daimler AG (DDAIF) initiated with a Buy at Citi... Engility (EGL) initiated with a Buy at Jefferies... Euronet (EEFT) initiated with an Outperform at Northland... Evolent Health (EVH) initiated with an Outperform at Cowen... Ferrari (RACE) initiated with a Neutral at Citi... Fiat Chrysler (FCAU) initiated with a Neutral at Citi... Franco-Nevada (FNV) initiated with a Neutral at JPMorgan... Gilead (GILD) initiated with an Outperform at Credit Suisse... Huntington Ingalls (HII) initiated with a Buy at Guggenheim... Incyte (INCY) initiated with an Outperform at Credit Suisse... LeMaitre (LMAT) initiated with a Neutral at Sidoti... Lockheed Martin (LMT) initiated with a Buy at Guggenheim... ManTech (MANT) initiated with an Underperform at Jefferies... Mesoblast (MESO) initiated with an Outperform at Credit Suisse... PTC Therapeutics (PTCT) initiated with an Outperform at Credit Suisse... Phillips 66 Partners (PSXP) initiated with a Neutral at Mitsubishi UFJ... Regeneron (REGN) initiated with a Neutral at Credit Suisse... Sykes Enterprises (SYKE) initiated with a Market Perform at Barrington... Vertex (VRTX) initiated with an Outperform at Credit Suisse... Volkswagen (VLKAY) initiated with a Buy at Citi... XenoPort (XNPT) initiated with an Underperform at Credit Suisse.

Vertex Pharmaceuticals announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor. Following the positive Phase 3 results in acute pain announced in January, the FDA has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain. Vertex has started the rolling submission process and is on track to complete the submission in the second quarter of 2024. Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain. In neuropathic pain, Vertex released positive results from its Phase 2 study in December 2023 and recently completed a successful end-of-phase 2 meeting with the FDA. Vertex is now preparing to initiate a Phase 3 pivotal program of suzetrigine in patients with DPN in 2H 2024. In addition, the FDA recently granted suzetrigine Breakthrough Therapy designation for the treatment of pain associated with DPN. The Phase 3 program will include two identical 12-week randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of suzetrigine in patients with DPN. The primary endpoint for both studies will be the change from baseline in weekly average of daily pain intensity on the numeric pain rating scale, or NPRS, assessed at Week 12 compared to placebo. Both studies will also include a key secondary endpoint of change from baseline in the weekly average of daily pain intensity on the NPRS at Week 12 compared to pregabalin. Approximately 1,100 patients are expected to enroll in each Phase 3 study. After completing participation in the randomized controlled studies, patients may roll over into an open-label study to evaluate the long-term safety and effectiveness of suzetrigine in DPN. Additionally, Vertex continues to enroll its Phase 2 study of suzetrigine in patients with lumbosacral radiculopathy, or LSR, which is pain caused by impairment or injury to nerve roots in the area of the lumbar spine. The company is on track to complete enrollment in the Phase 2 LSR study by the end of the year.

Amgen "provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE(R) in chronic obstructive pulmonary disease, or COPD, which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. We are encouraged by the results of the COURSE Phase 2a proof-of-concept trial, which investigated tezepelumab in moderate to very severe COPD patients, across a broad range of eosinophil levels, irrespective of inflammatory drivers, emphysema, chronic bronchitis and smoking status. This study did not exclude any patients based on their baseline eosinophil count (BEC) and intentionally enrolled patients with a broad range of BECs. Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: -6, 36; p=0.1042). Of note, more reductions were observed in a prespecified subgroup of patients with BEC greater than or equal to150 cells/muL (37% [95% CI: 7, 57]). The trend in reduction was greater in a small number of subjects with BEC greater than or equal to300 cells/microL."